Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer
- 25 August 2020
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 28 (3-4) , 175-187
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (C5759/A20971)
- None
This publication has 116 references indexed in Scilit:
- The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancerBMC Cancer, 2013
- Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expressionBMC Cancer, 2013
- The Noncoding RNA Expression Profile and the Effect of lncRNA AK126698 on Cisplatin Resistance in Non-Small-Cell Lung Cancer CellPLOS ONE, 2013
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceClinical Cancer Research, 2013
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclassesGenes & Development, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Long non-coding RNAs: insights into functionsNature Reviews Genetics, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007